TD Asset Management
MRTX

TD Asset Management’s Mirati Therapeutics, Inc. Common Stock MRTX Stock Holding History

TD Asset Management’s Portfolio MRTX Stock Details MRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-213,218
Closed -$9.29M – 1470
2023
Q3 		$9.29M Buy
213,218
+141,113
+196% +$5.04M 0.01% 600
2023
Q2 		$2.61M Buy
72,105
+4,700
+7% +$194K ﹤0.01% 898
2023
Q1 		$2.51M Buy
67,405
+13,300
+25% +$598K ﹤0.01% 914
2022
Q4 		$2.45M Buy
54,105
+22,970
+74% +$1.49M ﹤0.01% 928
2022
Q3 		$2.18M Hold
31,135
– – ﹤0.01% 975
2022
Q2 		$2.09M Sell
31,135
-16,100
-34% -$1.02M ﹤0.01% 996
2022
Q1 		$3.88M Sell
47,235
-15,796
-25% -$1.62M ﹤0.01% 883
2021
Q4 		$9.25M Buy
63,031
+1,700
+3% +$264K 0.01% 699
2021
Q3 		$10.8M Buy
61,331
+4,091
+7% +$658K 0.01% 633
2021
Q2 		$9.16M Buy
57,240
+20,186
+54% +$3.24M 0.01% 671
2021
Q1 		$6.35M Buy
37,054
+1,710
+5% +$339K 0.01% 762
2020
Q4 		$7.76M Buy
35,344
+9,154
+35% +$1.98M 0.01% 669
2020
Q3 		$4.35M Buy
26,190
+1,000
+4% +$137K 0.01% 741
2020
Q2 		$2.88M Buy
25,190
+2,500
+11% +$242K ﹤0.01% 794
2020
Q1 		$1.74M Sell
22,690
-5,787
-20% -$519K ﹤0.01% 861
2019
Q4 		$3.67M Sell
28,477
-1,700
-6% -$164K 0.01% 787
2019
Q3 		$2.35M Buy
30,177
+2,777
+10% +$261K ﹤0.01% 876
2019
Q2 		$2.82M Buy
27,400
+7,800
+40% +$607K ﹤0.01% 836
2019
Q1 		$1.44M Buy
19,600
+3,800
+24% +$259K ﹤0.01% 976
2018
Q4 		$670K Buy
15,800
+300
+2% +$12K ﹤0.01% 1158
2018
Q3 		$730K Buy
15,500
+7,300
+89% +$406K ﹤0.01% 1223
2018
Q2 		$404K Buy
8,200
+200
+3% +$7.55K ﹤0.01% 1306
2018
Q1 		$246K Buy
+8,000
New +$222K ﹤0.01% 1298

Other funds holding MRTX

Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
SS
Simplicity Solutions Minneapolis, Minnesota $3.66B AUM 23.51% 1-Year Est. Return
B
Braslyn New Providence, Bahamas $7.81M AUM 338.68% 1-Year Est. Return

TD Asset Management's MRTX Position: Q4 2023 in Review

TD Asset Management sold out of Mirati Therapeutics, Inc. Common Stock (MRTX) in Q4 2023, closing a stake of 213,218 shares — an estimated $9.29M sold.

TD Asset Management first reported a position in MRTX in Q1 2018 and held it in 23 quarters. The position peaked at $10.8M in Q3 2021. 217 funds tracked by Wall St. Rank hold MRTX as of Q4 2023.

  • TD Asset Management reported no remaining Mirati Therapeutics, Inc. Common Stock position as of Q4 2023 after selling out during the quarter.
  • TD Asset Management sold 213,218 Mirati Therapeutics, Inc. Common Stock shares in Q4 2023, an estimated $9.29M.
  • TD Asset Management first reported a position in Mirati Therapeutics, Inc. Common Stock in Q1 2018 and held it in 23 quarters.
  • TD Asset Management's Mirati Therapeutics, Inc. Common Stock position peaked at $10.8M in Q3 2021.
  • 217 funds tracked by Wall St. Rank held Mirati Therapeutics, Inc. Common Stock as of Q4 2023.

Based on TD Asset Management's 13F filing for Q4 2023, filed 12 Feb 2024.